Zkusit zdarma
Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc.

RLMD
Cena:
$ 7.04
-0.17 (-2.36%)
Valuace
70
Růst
53
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Relmada Therapeutics Q1 Earnings Call Highlights

Relmada Therapeutics Q1 Earnings Call Highlights

22:06 12-05-2026

Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrationa...

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript

21:30 12-05-2026

Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript...

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026

7:00 06-05-2026

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026

7:00 05-05-2026

CORAL GABLES, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Re...

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

10:55 13-04-2026

The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the ...

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

10:56 26-03-2026

The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 92.2% upside in the ...

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript

22:12 19-03-2026

Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript...

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

16:01 19-03-2026

CORAL GABLES, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “...

RLMD Stock Surges 42% in a Week: Here's What You Should Know

RLMD Stock Surges 42% in a Week: Here's What You Should Know

14:06 12-03-2026

Relmada Therapeutics jumps 42% in a week after reporting encouraging efficacy and safety data from a...

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026

7:00 12-03-2026

CORAL GABLES, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “...

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing

7:05 09-03-2026

CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “...

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% – Here’s Why

Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% – Here’s Why

4:48 20-02-2026

Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) traded up 6.9% on Thursday. The company ...

Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00

Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00

1:11 01-02-2026

Shares of Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) have received a consensus rati...

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

7:00 12-01-2026

FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractor...

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

7:30 03-12-2025

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle inva...

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript

19:21 13-11-2025

Relmada Therapeutics, Inc. ( RLMD ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Part...

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates

16:01 13-11-2025

Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-mus...

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

7:30 07-11-2025

CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “R...

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

7:09 04-11-2025

CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “R...

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer

7:01 04-11-2025

Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potenti...

close

RELMADA THERAPEUTICS PROVIDES REGULATORY UPDATE CONFIRMING FDA ALIGNMENT ON REGISTRATIONAL STUDIES DESIGN FOR NDV-01 FOR TWO SEPARATE INDICATIONS

12-01-2026
FDA WRITTEN FEEDBACK SUPPORTS: - A SINGLE-ARM, OPEN-LABEL REGISTRATIONAL TRIAL IN 2ND-LINE REFRACTOR...
Více zde

RELMADA THERAPEUTICS ANNOUNCES PRESENTATION OF NDV-01 PHASE 2 DATA AT THE SOCIETY FOR UROLOGIC ONCOLOGY

03-12-2025
POSTER HIGHLIGHTS 6-MONTH FOLLOW-UP DATA FROM THE ONGOING PHASE 2 TRIAL OF NDV-01 IN NON-MUSCLE INVA...
Více zde

RELMADA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES KEY CLINICAL, REGULATORY, AND CORPORATE UPDATES

13-11-2025
POSITIVE 9-MONTH FOLLOW-UP DATA FOR NDV-01 SHOWED A 92% OVERALL RESPONSE RATE AT ANY TIME IN NON-MUS...
Více zde

RELMADA THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 13, 2025

07-11-2025
CORAL GABLES, FLA., NOV. 07, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “R...
Více zde

RELMADA THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

04-11-2025
CORAL GABLES, FLA., NOV. 04, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “R...
Více zde

RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER

04-11-2025
ANNOUNCES NDV-01 9-MONTH FOLLOW-UP SAFETY AND EFFICACY DATA IN NMIBC FDA FEEDBACK SUPPORTS 2 POTENTI...
Více zde

RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01

07-10-2025
DR. KATES' EXPERIENCE AS CHAIR OF THE LANDMARK PHASE 3 BRIDGE BLADDER CANCER TRIAL AND DEDICATION TO...
Více zde

RELMADA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

16-09-2025
CORAL GABLES, FLA., SEPT. 16, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “...
Více zde

RELMADA ISSUES MID-YEAR CEO LETTER TO SHAREHOLDERS

10-09-2025
CORAL GABLES, FLA., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “...
Více zde

RELMADA THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, AUGUST 7, 2025

31-07-2025
CORAL GABLES, FLA., JULY 31, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “R...
Více zde

RELMADA THERAPEUTICS APPOINTS RENOWNED UROLOGIC ONCOLOGIST, YAIR LOTAN, MD, TO CHAIR THE CLINICAL ADVISORY BOARD AND SUPPORT DEVELOPMENT OF NDV-01

15-07-2025
DR. LOTAN'S DISTINGUISHED EXPERTISE IN BLADDER CANCER CARE AND CLINICAL DEVELOPMENT BRINGS FURTHER S...
Více zde

DIMERX APPOINTS BIOTECH LEADER SERGIO TRAVERSA, PHARMD, TO BOARD OF DIRECTORS

09-07-2025
APPOINTMENT HIGHLIGHTS DIMERX'S NEXT PHASE OF GROWTH AS IT ADVANCES NON-ADDICTIVE PAIN THERAPEUTICS ...
Více zde

RELMADA THERAPEUTICS APPOINTS UROLOGY EXPERT RAJ S. PRUTHI, MD AS CMO-UROLOGY

17-06-2025
DR. PRUTHI BRINGS VAST CLINICAL DEVELOPMENT EXPERIENCE ADVANCING NOVEL THERAPIES FOR NMIBC TO RELMAD...
Více zde

RELMADA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

12-05-2025
POSITIVE INITIAL PHASE 2 PROOF-OF-CONCEPT DATA FOR NDV-01 AT AUA 2025 SHOWING A 90% OVERALL RESPONSE...
Více zde

RELMADA THERAPEUTICS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MONDAY, MAY 12, 2025

08-05-2025
CORAL GABLES, FLA., MAY 08, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “RE...
Více zde

RELMADA THERAPEUTICS PRESENTS POSITIVE INITIAL PHASE 2 NDV-01 DATA AT AUA2025

28-04-2025
90% OF PATIENTS ACHIEVED HIGH GRADE DISEASE-FREE STATUS AT ANY TIME POINT WITH NDV-01, DEMONSTRATING...
Více zde

UPDATE -- RELMADA THERAPEUTICS TO PRESENT NDV-01 DATA AT AUA2025

27-04-2025
DATA TO BE PRESENTED IN CLINICAL TRIALS IN PROGRESS SESSION ON MONDAY, APRIL 28, 2025 DATA TO BE PRE...
Více zde

RELMADA THERAPEUTICS TO HOST KOL EVENT ON PHASE 2 NDV-01 DATA

24-04-2025
APRIL 28 TH AUA DATA PRESENTATION TO HIGHLIGHT STUDY IN PATIENTS WITH HIGH-GRADE  NON-MUSCLE INVASI...
Více zde

UPDATE -- RELMADA THERAPEUTICS TO PRESENT NDV-01 DATA AT AUA2025

14-04-2025
CORAL GABLES, FLA., APRIL 14, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “...
Více zde

RELMADA THERAPEUTICS TO PRESENT NDV-01 DATA AT AUA2025

14-04-2025
CORAL GABLES, FLA., APRIL 14, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “...
Více zde

RELMADA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS AND PROVIDES BUSINESS UPDATE

27-03-2025
EXPECT TOPLINE PHASE 2 DATA FOR NDV-01 FOR HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER  (HG-NMIBC...
Více zde

RELMADA THERAPEUTICS TO REPORT FOURTH QUARTER 2024 FINANCIAL RESULTS ON THURSDAY, MARCH 27, 2025

26-03-2025
CORAL GABLES, FLA., MARCH 26, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, “...
Více zde

RELMADA THERAPEUTICS LICENSES PHASE 2 BLADDER CANCER CANDIDATE, NDV-01, FROM TRIGONE PHARMA, LTD.

25-03-2025
NDV-01 IS A NOVEL, SUSTAINED-RELEASE, INTRAVESICAL GEMCITABINE/DOCETAXEL, READY-FOR-USE PRODUCT CAND...
Více zde

RELMADA THERAPEUTICS ACQUIRES POTENTIAL THERAPY FOR TOURETTE SYNDROME FROM ASARINA PHARMA AB

06-02-2025
RELMADA PURCHASES SEPRANOLONE, A PHASE 2B READY ASSET, FOR THE TREATMENT OF TOURETTE SYNDROME (TS) A...
Více zde

RELMADA THERAPEUTICS TO DISCONTINUE THE RELIANCE II AND RELIGHT PHASE 3 STUDIES OF REL-1017

09-12-2024
RELMADA THERAPEUTICS HAS COMMENCED A PROCESS TO EXPLORE STRATEGIC ALTERNATIVES TO MAXIMIZE SHAREHOLD...
Více zde

RELMADA THERAPEUTICS REPORTS THAT DATA MONITORING COMMITTEE (DMC) ASSESSMENT INDICATES THAT THE PHASE 3 RELIANCE II TRIAL IS FUTILE AT ITS INTERIM ANALYSIS AND IS UNLIKELY TO MEET THE PRIMARY EFFICACY ENDPOINT WITH STATISTICAL SIGNIFICANCE

04-12-2024
THE DMC DID NOT IDENTIFY ANY NEW SAFETY CONCERNS RELMADA TO EVALUATE POTENTIAL NEXT STEPS FOR THE RE...
Více zde

KUEHN LAW ENCOURAGES INVESTORS OF RELMADA THERAPEUTICS, INC. TO CONTACT LAW FIRM

21-11-2024
NEW YORK, NOV. 21, 2024 (GLOBE NEWSWIRE) -- KUEHN LAW, PLLC, A SHAREHOLDER LITIGATION LAW FIRM, IS I...
Více zde

RELMADA THERAPEUTICS INITIATES PHASE 1 DOSING WITH REL-P11 FOR METABOLIC DISEASE

14-11-2024
REL-P11 IS A PROPRIETARY, LOW-DOSE, MODIFIED-RELEASE PSILOCYBIN FORMULATION SINGLE-ASCENDING DOSING ...
Více zde

RELMADA THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-11-2024
PRE-PLANNED PHASE 3 RELIANCE II INTERIM ANALYSIS, ANTICIPATED BY YE 2024, COULD REPRESENT AN IMPORTA...
Více zde

RELMADA THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-11-2024
PRE-PLANNED PHASE 3 RELIANCE II INTERIM ANALYSIS, ANTICIPATED BY YE 2024, COULD REPRESENT AN IMPORTA...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-12-15 00:00:008-KStáhnout
2025-11-13 00:00:008-KStáhnout
2025-11-13 00:00:0010-QStáhnout
2025-11-05 00:00:008-KStáhnout
2025-11-04 00:00:008-KStáhnout
2025-09-17 01:00:008-KStáhnout
2025-09-17 00:00:008-KStáhnout
2025-09-16 01:00:008-KStáhnout
2025-09-16 00:00:008-KStáhnout
2025-09-10 01:00:008-KStáhnout
2025-09-10 00:00:008-KStáhnout
2025-09-02 01:00:008-KStáhnout
2025-09-02 00:00:008-KStáhnout
2025-08-07 01:00:008-KStáhnout
2025-08-07 01:00:0010-QStáhnout
2025-08-07 00:00:008-KStáhnout
2025-08-07 00:00:0010-QStáhnout
2025-07-23 01:00:008-KStáhnout
2025-07-23 00:00:008-KStáhnout
2025-07-10 01:00:008-KStáhnout
2025-07-10 00:00:008-KStáhnout
2025-06-18 01:00:008-KStáhnout
2025-06-18 00:00:008-KStáhnout
2025-05-27 01:00:008-KStáhnout
2025-05-27 00:00:008-KStáhnout
2025-05-12 01:00:008-KStáhnout
2025-05-12 01:00:0010-QStáhnout
2025-05-12 00:00:008-KStáhnout
2025-05-12 00:00:0010-QStáhnout
2025-04-28 01:00:008-KStáhnout
2025-04-28 00:00:008-KStáhnout
2025-03-27 00:00:008-KStáhnout
2025-03-27 00:00:0010-KStáhnout
2025-03-26 23:00:008-KStáhnout
2025-03-26 23:00:0010-KStáhnout
2025-03-26 00:00:008-KStáhnout
2025-03-25 23:00:008-KStáhnout
2025-02-06 00:00:008-KStáhnout
2025-02-05 23:00:008-KStáhnout
2025-01-27 00:00:008-KStáhnout
2025-01-26 23:00:008-KStáhnout
2025-01-06 00:00:008-KStáhnout
2025-01-05 23:00:008-KStáhnout
2024-12-09 00:00:008-KStáhnout
2024-12-08 23:00:008-KStáhnout
2024-12-04 00:00:008-KStáhnout
2024-12-03 23:00:008-KStáhnout
2024-11-07 00:00:0010-QStáhnout
2024-11-06 23:00:0010-QStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-05-30 01:00:008-KStáhnout
2024-05-30 00:00:008-KStáhnout
2024-05-08 01:00:0010-QStáhnout
2024-05-08 00:00:0010-QStáhnout
2024-03-19 00:00:008-KStáhnout
2024-03-19 00:00:0010-KStáhnout
2024-03-18 23:00:008-KStáhnout
2024-03-18 23:00:0010-KStáhnout
2024-01-11 00:00:008-KStáhnout
2024-01-10 23:00:008-KStáhnout
2024-01-04 00:00:008-KStáhnout
2024-01-03 23:00:008-KStáhnout
2024-01-03 00:00:008-KStáhnout
2024-01-02 23:00:008-KStáhnout
2023-11-08 00:00:008-KStáhnout
2023-11-08 00:00:0010-QStáhnout
2023-11-07 23:00:008-KStáhnout
2023-11-07 23:00:0010-QStáhnout
2023-10-11 01:00:008-KStáhnout
2023-10-11 00:00:008-KStáhnout
2023-10-10 01:00:008-KStáhnout
2023-10-10 00:00:008-KStáhnout
2023-10-04 01:00:008-KStáhnout
2023-10-04 00:00:008-KStáhnout
2023-09-20 01:00:008-KStáhnout
2023-09-20 00:00:008-KStáhnout
2023-09-06 01:00:008-KStáhnout
2023-09-06 00:00:008-KStáhnout
2023-08-10 01:00:008-KStáhnout
2023-08-10 00:00:008-KStáhnout
2023-08-08 01:00:008-KStáhnout
2023-08-08 01:00:0010-QStáhnout
2023-08-08 00:00:008-KStáhnout
2023-08-08 00:00:0010-QStáhnout
2023-05-25 01:00:008-KStáhnout
2023-05-25 00:00:008-KStáhnout
2023-05-15 01:00:008-KStáhnout
2023-05-15 00:00:008-KStáhnout
2023-05-11 01:00:008-KStáhnout
2023-05-11 01:00:0010-QStáhnout
2023-05-11 00:00:008-KStáhnout
2023-05-11 00:00:0010-QStáhnout
2023-04-19 01:00:008-KStáhnout
2023-04-19 00:00:008-KStáhnout
2023-03-23 00:00:008-KStáhnout
2023-03-23 00:00:0010-KStáhnout
2023-03-22 23:00:008-KStáhnout
2023-03-22 23:00:0010-KStáhnout
2023-03-13 00:00:008-KStáhnout
2023-03-12 23:00:008-KStáhnout
2023-01-17 00:00:008-KStáhnout
2023-01-16 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2023-01-05 00:00:008-KStáhnout
2023-01-04 23:00:008-KStáhnout
2022-12-28 00:00:008-KStáhnout
2022-12-27 23:00:008-KStáhnout
2022-12-07 00:00:008-KStáhnout
2022-12-06 23:00:008-KStáhnout
2022-11-14 00:00:008-KStáhnout
2022-11-13 23:00:008-KStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-10 00:00:0010-QStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-09 23:00:0010-QStáhnout
2022-10-13 01:00:008-KStáhnout
2022-10-13 00:00:008-KStáhnout
2022-09-22 01:00:008-KStáhnout
2022-09-22 00:00:008-KStáhnout
2022-09-20 01:00:008-KStáhnout
2022-09-20 00:00:008-KStáhnout
2022-08-11 01:00:0010-QStáhnout
2022-08-11 00:00:0010-QStáhnout
2022-06-01 01:00:008-KStáhnout
2022-06-01 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-03-25 00:00:0010-KStáhnout
2022-03-24 23:00:0010-KStáhnout
2022-03-23 00:00:008-KStáhnout
2022-03-22 23:00:008-KStáhnout
2022-03-07 00:00:008-KStáhnout
2022-03-06 23:00:008-KStáhnout
2022-02-23 00:00:008-KStáhnout
2022-02-22 23:00:008-KStáhnout
2021-12-22 00:00:008-KStáhnout
2021-12-21 23:00:008-KStáhnout
2021-12-20 00:00:008-KStáhnout
2021-12-19 23:00:008-KStáhnout
2021-12-13 00:00:008-KStáhnout
2021-12-12 23:00:008-KStáhnout
2021-12-07 00:00:008-KStáhnout
2021-12-06 23:00:008-KStáhnout
2021-11-23 00:00:008-KStáhnout
2021-11-22 23:00:008-KStáhnout
2021-11-15 00:00:008-KStáhnout
2021-11-14 23:00:008-KStáhnout
2021-11-12 00:00:0010-QStáhnout
2021-11-11 23:00:0010-QStáhnout
2021-10-07 01:00:008-KStáhnout
2021-10-07 00:00:008-KStáhnout
2021-08-10 01:00:0010-QStáhnout
2021-08-10 00:00:0010-QStáhnout
2021-07-20 01:00:008-KStáhnout
2021-07-20 00:00:008-KStáhnout
2021-05-20 01:00:008-KStáhnout
2021-05-20 00:00:008-KStáhnout
2021-05-12 01:00:0010-QStáhnout
2021-05-12 00:00:0010-QStáhnout
2021-03-24 00:00:0010-KStáhnout
2021-03-23 23:00:0010-KStáhnout
2021-03-23 00:00:008-KStáhnout
2021-03-22 23:00:008-KStáhnout
2021-03-15 00:00:008-KStáhnout
2021-03-14 23:00:008-KStáhnout
2021-01-07 00:00:008-KStáhnout
2021-01-06 23:00:008-KStáhnout
2021-01-05 00:00:008-KStáhnout
2021-01-04 23:00:008-KStáhnout
2020-12-14 00:00:008-KStáhnout
2020-12-13 23:00:008-KStáhnout
2020-12-08 00:00:008-KStáhnout
2020-12-07 23:00:008-KStáhnout
2020-11-16 00:00:008-KStáhnout
2020-11-15 23:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-10-27 00:00:008-KStáhnout
2020-10-26 23:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-06-03 01:00:008-KStáhnout
2020-06-03 00:00:008-KStáhnout
2020-05-15 01:00:0010-QStáhnout
2020-05-15 00:00:0010-QStáhnout
2020-03-12 00:00:008-KStáhnout
2020-03-11 23:00:008-KStáhnout
2020-03-09 00:00:008-KStáhnout
2020-03-08 23:00:008-KStáhnout
2020-01-10 00:00:008-KStáhnout
2020-01-09 23:00:008-KStáhnout
2019-12-26 00:00:008-KStáhnout
2019-12-25 23:00:008-KStáhnout
2019-12-06 00:00:008-KStáhnout
2019-12-05 23:00:008-KStáhnout
2019-12-03 00:00:008-KStáhnout
2019-12-02 23:00:008-KStáhnout
2019-11-13 00:00:0010-QStáhnout
2019-11-12 23:00:0010-QStáhnout
2019-10-21 01:00:008-KStáhnout
2019-10-21 00:00:008-KStáhnout
2019-10-18 01:00:008-KStáhnout
2019-10-18 00:00:008-KStáhnout
2019-10-01 01:00:008-KStáhnout
2019-10-01 00:00:008-KStáhnout
2019-09-27 01:00:008-KStáhnout
2019-09-27 00:00:008-KStáhnout
2019-09-24 01:00:0010-KStáhnout
2019-09-24 00:00:0010-KStáhnout
2019-07-29 01:00:008-KStáhnout
2019-07-29 00:00:008-KStáhnout
2019-07-17 01:00:008-KStáhnout
2019-07-17 00:00:008-KStáhnout
2019-06-20 01:00:008-KStáhnout
2019-06-20 00:00:008-KStáhnout
2019-05-15 01:00:0010-QStáhnout
2019-05-15 00:00:0010-QStáhnout
2019-04-15 01:00:008-KStáhnout
2019-04-15 00:00:008-KStáhnout
2019-02-28 00:00:008-KStáhnout
2019-02-27 23:00:008-KStáhnout
2019-02-13 00:00:0010-QStáhnout
2019-02-12 23:00:0010-QStáhnout
2019-02-11 00:00:008-KStáhnout
2019-02-10 23:00:008-KStáhnout
2019-01-04 00:00:008-KStáhnout
2019-01-03 23:00:008-KStáhnout
2018-12-10 00:00:008-KStáhnout
2018-12-09 23:00:008-KStáhnout
2018-11-13 00:00:0010-QStáhnout
2018-11-12 23:00:0010-QStáhnout
2018-11-08 00:00:008-KStáhnout
2018-11-07 23:00:008-KStáhnout
2018-10-18 01:00:008-KStáhnout
2018-10-18 00:00:008-KStáhnout
2018-09-28 01:00:0010-KStáhnout
2018-09-28 00:00:0010-KStáhnout
2018-08-17 01:00:008-KStáhnout
2018-08-17 00:00:008-KStáhnout
2018-05-14 01:00:0010-QStáhnout
2018-05-14 00:00:0010-QStáhnout
2018-04-05 01:00:008-KStáhnout
2018-04-05 00:00:008-KStáhnout
2018-04-02 01:00:008-KStáhnout
2018-04-02 00:00:008-KStáhnout
2018-02-12 00:00:0010-QStáhnout
2018-02-11 23:00:0010-QStáhnout
2018-02-05 00:00:008-KStáhnout
2018-02-04 23:00:008-KStáhnout
2018-01-19 00:00:008-KStáhnout
2018-01-18 23:00:008-KStáhnout
2017-11-14 00:00:0010-QStáhnout
2017-11-13 23:00:0010-QStáhnout
2017-10-04 01:00:008-KStáhnout
2017-10-04 00:00:008-KStáhnout
2017-09-28 01:00:0010-KStáhnout
2017-09-28 00:00:0010-KStáhnout
2017-06-15 01:00:008-KStáhnout
2017-06-15 00:00:008-KStáhnout
2017-06-08 01:00:008-KStáhnout
2017-06-08 00:00:008-KStáhnout
2017-05-18 01:00:008-KStáhnout
2017-05-18 00:00:008-KStáhnout
2017-05-15 01:00:0010-QStáhnout
2017-05-15 00:00:0010-QStáhnout
2017-04-27 01:00:008-KStáhnout
2017-04-27 00:00:008-KStáhnout
2017-02-17 00:00:008-KStáhnout
2017-02-16 23:00:008-KStáhnout
2017-02-10 00:00:0010-QStáhnout
2017-02-09 23:00:0010-QStáhnout
2017-02-01 00:00:008-KStáhnout
2017-01-31 23:00:008-KStáhnout
2016-11-10 00:00:0010-QStáhnout
2016-11-09 23:00:0010-QStáhnout
2016-09-12 01:00:008-KStáhnout
2016-09-12 00:00:008-KStáhnout
2016-09-09 01:00:0010-KStáhnout
2016-09-09 00:00:0010-KStáhnout
2016-06-17 01:00:008-KStáhnout
2016-06-17 00:00:008-KStáhnout
2016-05-13 01:00:008-KStáhnout
2016-05-13 00:00:008-KStáhnout
2016-05-09 01:00:0010-QStáhnout
2016-05-09 00:00:0010-QStáhnout
2016-02-05 00:00:0010-QStáhnout
2016-02-04 23:00:0010-QStáhnout
2016-01-13 00:00:008-KStáhnout
2016-01-12 23:00:008-KStáhnout
2015-12-31 00:00:008-KStáhnout
2015-12-30 23:00:008-KStáhnout
2015-12-30 00:00:008-KStáhnout
2015-12-29 23:00:008-KStáhnout
2015-12-23 00:00:008-KStáhnout
2015-12-22 23:00:008-KStáhnout
2015-12-14 00:00:008-KStáhnout
2015-12-13 23:00:008-KStáhnout
2015-12-11 00:00:008-KStáhnout
2015-12-10 23:00:008-KStáhnout
2015-12-10 00:00:008-KStáhnout
2015-12-09 23:00:008-KStáhnout
2015-12-09 00:00:008-KStáhnout
2015-12-08 23:00:008-KStáhnout
2015-11-25 00:00:008-KStáhnout
2015-11-24 23:00:008-KStáhnout
2015-11-12 00:00:008-KStáhnout
2015-11-11 23:00:008-KStáhnout
2015-11-06 00:00:0010-QStáhnout
2015-11-05 23:00:0010-QStáhnout
2015-11-05 00:00:008-KStáhnout
2015-11-04 23:00:008-KStáhnout
2015-10-02 01:00:008-KStáhnout
2015-10-02 00:00:008-KStáhnout
2015-09-23 01:00:008-KStáhnout
2015-09-23 00:00:008-KStáhnout
2015-09-11 01:00:0010-KStáhnout
2015-09-11 00:00:0010-KStáhnout
2015-08-10 01:00:008-KStáhnout
2015-08-10 00:00:008-KStáhnout
2015-08-07 01:00:008-KStáhnout
2015-08-07 00:00:008-KStáhnout
2015-07-16 01:00:008-KStáhnout
2015-07-16 00:00:008-KStáhnout
2015-06-15 01:00:008-KStáhnout
2015-06-15 00:00:008-KStáhnout
2015-05-22 01:00:008-KStáhnout
2015-05-22 00:00:008-KStáhnout
2015-05-15 01:00:0010-QStáhnout
2015-05-15 00:00:0010-QStáhnout
2015-04-23 01:00:008-KStáhnout
2015-04-23 00:00:008-KStáhnout
2015-02-13 00:00:0010-QStáhnout
2015-02-12 23:00:0010-QStáhnout
2014-12-23 00:00:008-KStáhnout
2014-12-22 23:00:008-KStáhnout
2014-11-07 00:00:0010-QStáhnout
2014-11-06 23:00:0010-QStáhnout
2014-10-16 01:00:008-KStáhnout
2014-10-16 00:00:008-KStáhnout
2014-09-11 01:00:008-KStáhnout
2014-09-11 00:00:008-KStáhnout
2014-09-09 01:00:008-KStáhnout
2014-09-09 00:00:008-KStáhnout
2014-08-07 01:00:008-KStáhnout
2014-08-07 00:00:008-KStáhnout
2014-07-14 01:00:008-KStáhnout
2014-07-14 00:00:008-KStáhnout
2014-06-16 01:00:008-KStáhnout
2014-06-16 00:00:008-KStáhnout
2014-06-02 01:00:008-KStáhnout
2014-06-02 00:00:008-KStáhnout
2014-05-27 01:00:008-KStáhnout
2014-05-27 00:00:008-KStáhnout
2014-05-19 01:00:008-KStáhnout
2014-05-19 00:00:008-KStáhnout
2014-05-05 01:00:008-KStáhnout
2014-05-05 00:00:008-KStáhnout
2014-04-15 01:00:0010-QStáhnout
2014-04-15 00:00:0010-QStáhnout
2014-01-13 00:00:0010-QStáhnout
2014-01-12 23:00:0010-QStáhnout
2013-12-16 00:00:0010-KStáhnout
2013-12-15 23:00:0010-KStáhnout
2013-07-12 01:00:0010-QStáhnout
2013-07-12 00:00:0010-QStáhnout
2013-05-03 01:00:0010-QStáhnout
2013-05-03 00:00:0010-QStáhnout
preloader